Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma

INTRODUCTION: Geographic access to novel oncology therapies, and the extent to which it may vary by potential sites of care, regions, and population characteristics, is poorly understood. We examined how expanding access to chimeric antigen receptor (CAR) T cell therapy administration sites impacts...

Descripción completa

Detalles Bibliográficos
Autores principales: Snyder, Sophie, Chung, Karen C., Jun, Monika P., Gitlin, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408091/
https://www.ncbi.nlm.nih.gov/pubmed/34302277
http://dx.doi.org/10.1007/s12325-021-01838-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408091/
https://www.ncbi.nlm.nih.gov/pubmed/34302277
http://dx.doi.org/10.1007/s12325-021-01838-z

Ejemplares similares